掌心里characterise的良研培訓(xùn)
GCP | 培訓(xùn) | 交流 | 分享
High-quality data to empower data-driven medicines regulation in the European Union
News 10/10/2022
emA and the Heads of Medicines Agencies (HMA) in the EU Member States are moving ahead with their ambitious agenda to increase access and improve the quality of the data that underpin decision-making on the benefits and risks of medicines in the European Union (EU).
The joint Big Data Steering Group set up by EMA and the Heads of Medicines Agencies (HMA) has endorsed two documents for public consultation, one looking at the quality of all data types used in regulatory decision-making, the other one focusing specifically on the discoverability of real-world data.
Quality of data is key to data-driven regulation
Data quality is a critical element for realising the full potential of data-driven regulation and supports the trust of patients and healthcare professionals. The draft Data Quality Framework for EU medicine regulation, now open for public consultation, sets out quality criteria for data used in medicine regulation to ensure they are fit for purpose to support benefit-risk decisions.
The framework addresses principles and procedures that apply across data types and across regulatory activities. It also provides considerations on data quality, definitions for data dimensions and sub-dimensions, as well as their characterisation and related metrics. The framework seeks to provide a coherent umbrella to identify, define and further develop data quality assessment procedures and recommendations for current and novel data types.
The draft Data Quality Framework has been produced by EMA, HMA and the Towards the European Health Data Space (TEHDAS) Joint Action. The public consultation is open until 18 November 2022.
EMA, HMA and TEHDAS consulted a wide range of stakeholders during the development of this framework and organised a workshop in April 2022 to collect input from experts in the field and learn from existing experiences. A follow-up webinar will take place on 18 October to present the draft framework to interested stakeholders and support the public consultation.
The document will be updated regularly in line with developments including initiatives to support the European Health Data Space (EHDS) proposed by the European Commission.
First ever guide for the use of real-world metadata
The second document out for public consultation is a draft good practice guide for the use of the EU metadata catalogue of real-world data sources. It is the first guide produced worldwide to focus on metadata to empower systematic integration of real-world evidence in medicines regulation.
The guide provides recommendations on how to use the catalogue of real-world metadata that is currently being built and in late 2023 will replace the existing catalogue of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). The guide will help to identify suitable real-world data sources for studies and describes the metadata elements that will be used. The public consultation is open until 16 November 2022.
Real-world data are observational data stored in repositories such as electronic health records and disease registries. Metadata characterise real-world data and are essential to improve data discoverability, create a clearer understanding of their meaning and achieve greater reliability and quality when using them to improve the evidence available for benefit-risk decisions. Overall, they help to get better medicines to patients.
Data Quality Framework for EU medicines regulation
PDF閱讀下載：https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/data-quality-framework-eu-medicines-regulation_en.pdf
Good practice guide for the use of the Metadata Catalogue of Real-World Data Sources
PDF閱讀下載：https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-use-metadata-catalogue-real-world-data-sources_en.pdf
來源：European Medicines Agency 官網(wǎng) 2022年10月10日
點(diǎn)擊了解考試詳情 >>
藥物
2020版藥物臨床試驗(yàn)質(zhì)量管理規(guī)范（GCP）
網(wǎng)絡(luò)培訓(xùn)考試通知
器械
2022版器械臨床試驗(yàn)質(zhì)量管理規(guī)范（GCP）
網(wǎng)絡(luò)培訓(xùn)考試通知
臨床研究倫理審查
網(wǎng)絡(luò)培訓(xùn)考試通知
征文令
◤我們渴望眾人發(fā)聲 用文字傳遞知識(shí)◢
如果你喜歡用文字表達(dá)態(tài)度
請(qǐng)來金玉良研
與眾多研友們一起分享交流
只要你的來稿與臨床研究行業(yè)相關(guān)
知識(shí)點(diǎn)characterise，點(diǎn)評(píng)，建議，觀點(diǎn)......隨你選！
投稿方式： 發(fā)送至郵箱： liuyan@inmind-cn.com（郵件名稱： 來稿-姓名／昵稱）, 或者加TA微信（微信號(hào)： sarah28ly）
記得投稿時(shí)一定要留下聯(lián)系方式，若被選中發(fā)表，有稿費(fèi)支付！
小研
有話說
除金玉良研原創(chuàng)文章外，他人通過本平臺(tái)發(fā)布的原創(chuàng)文章及轉(zhuǎn)載文章觀點(diǎn)僅代表原作者本人，不代表本平臺(tái)立場(chǎng)。所發(fā)文字、圖片僅用于學(xué)習(xí)交流使用，并在顯要位置注明出處來源，如有侵權(quán)請(qǐng)聯(lián)系刪除！
良研相伴 一起在看
